Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
History
Rani Therapeutics was established in 2011 and has since become a top provider of Digital Pills, as well as other advanced GI treatments.
Mission
Rani Therapeutics’ mission is to provide compassionate care, innovative solutions and improved quality of life for patients with gastrointestinal diseases and disorders.
Vision
Our vision is to significantly reduce the burden of gastrointestinal diseases and lead to earlier diagnosis, improved treatments and better care.
